Nippon Kayaku To Start Cancer Drug NK102’s U.S. Phase II Trial
This article was originally published in PharmAsia News
Executive Summary
Nippon Kayaku plans to start a Phase II trial for cancer drug NK102 in the U.S. this spring. The trial targets intractable breast cancer patients and the selection of the trial facility has entered the final stage. NK102 is developed on a new drug delivery system that encapsulates active metabolite of cancer drug camptothecin with polymer micelle. According to the company, the drug's Phase I trial started in January 2007 in the U.S. showed promising results. The company has set developing polymer micelle cancer drug as a priority, and currently stomach cancer drug NK105 (paclitaxel) and pancreatic drug NK911 (doxorubicin) are in Phase II trials in Japan. (Click here for more - Japanese language
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.